Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Arasaradnam, Ramesh P.; McFarlane, M.; Ling, K.; Wurie, S.; O’Connell, N.; Nwokolo, Chuka U.; Bardhan, Karna Dev; Skinner, J.; Savage, Richard S.; Covington, James A. (2016)
Publisher: Institute of Physics Publishing Ltd.
Languages: English
Types: Article
Subjects: RC
he current diagnostic challenge with diagnosing hepatic encephalopathy (HE) is identifying those with minimal HE as opposed to the more clinically apparent covert/overt HE. Rifaximin, is an effective therapy but earlier identification and treatment of HE could prevent liver disease progression and hospitalization. Our pilot study aimed to analyse breath samples of patients with different HE grades, and controls, using a portable electronic (e) nose. 42 patients were enrolled; 22 with HE and 20 controls. Bedside breath samples were captured and analysed using an uvFAIMS machine (portable e-nose). West Haven criteria applied and MELD scores calculated. We classify HE patients from controls with a sensitivity and specificity of 0.88 (0.73-0.95) and 0.68 (0.51-0.81) respectively, AUROC 0.84 (0.75-0.93). Minimal HE was distinguishable from covert/overt HE with sensitivity of 0.79 and specificity of 0.5, AUROC 0.71 (0.57-0.84). This pilot study has highlighted the potential of breathomics to identify VOCs signatures in HE patients for diagnostic purposes. Importantly this was performed utilizing a non-invasive, portable bedside device and holds potential for future early HE diagnosis.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] Waghray A, Waghray N and Mullen K 2015 Management of covert hepatic encephalopathy J. Clin. Exp. Hepatol. 5 S75-81
    • [2] Bajaj J S, Cordoba J, Mullen K D, Amodio P, Shawcross D L, Butterworth R F and Morgan M Y (International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN)) 2011 Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement Aliment. Pharmacol. Ther. 33 739-47
    • [3] Stewart C A, Malinchoc M, Kim W R and Kamath P S 2007 Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease Liver Transpl. 13 1366-71
    • [4] Blei A T and Córdoba J 2001 Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy Am. J. Gastroenterol. 96 1968-76
    • [5] Jiang Q, Jiang X H, Zheng M H, Jiang L M, Chen Y P and Wang L 2008 Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis Eur. J. Gastroenterol. Hepatol. 20 1064-70
    • [6] Sharma B C, Sharma P, Lunia M K, Srivastava S, Goyal R and Sarin S K 2013 A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy Am. J. Gastroenterol. 108 1458-63
    • [7] Sidhu S S, Goyal O, Mishra B P, Sood A, Chhina R S and Soni R K 2011 Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial) Am. J. Gastroenterol. 106 307-16
    • [8] Bajaj J S, Heuman D M and Wade J B 2011 Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy Gastroenterology 140 478-87
    • [9] Arasaradnam R P et al 2014 Next generation diagnostic modalities in gastroenterology-gas phase volatile compound biomarker Aliment. Pharmacol. Ther. 39 780-9
    • [10] Peng G et al 2010 Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors Br. J. Cancer 10 542-51
    • [11] Arasaradnam R P et al 2013 A novel tool for noninvasive diagnosis and tracking of patients with inaflmmatory bowel disease Inaflmm. Bowel. Dis. 19 999-1003
    • [12] Covington J A et al 2012 The detection of patients at risk of gastrointestinal toxicity during pelvic radiotherapy by electronic nose and FAIMS: a pilot study Sensors (Basel) 12 13002-18
    • [13] Arasaradnam R P et al 2014 Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis PLoS One 9 e108750
    • [14] Arasaradnam R P et al 2014 Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis-a pilot study PLoS One 9 e107312
    • [15] Arasaradnam R P et al 2015 Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results J. Gastrointestinal Liver Disease 24 197-201
    • [16] Ilan Y 2007 Review article: the assessment of liver function using breath tests Aliment. Pharmacol. Ther. 26 1293-302
    • [17] Qin T et al 2010 The screening of volatile markers for hepatocellular carcinoma Cancer Epidemiol Biomarkers Prev. 19 2247-53
    • [18] Raman M et al 2013 Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease Clin. Gastroenterol. Hepatol. 11 868-75
    • [19] Wlodzimirow K A, Abu-Hanna A, Schultz M J, Maas M A, Bos L D, Sterk P J, Knobel H H, Soers R J and Chamuleau R A 2014 Exhaled breath analysis with electronic nose technology for detection of acute liver failure in rats Biosens. Bioelectron. 53 129-34
    • [20] Pereira J, Porto-Figueira P, Cavaco C, Taunk K, Rapole S, Dhakne R, Nagarajaram H and Câmara J S 2015 Breath analysis as a potential and non-invasive frontier in disease diagnosis: an overview Metabolites 5 3-55
    • [21] Wilson A D 2015 Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath Metabolites 5 140-63
    • [22] Arasaradnam R P et al 2009 Colonic fermentation-more than meets the nose Med. Hypotheses 73 753-6
    • [23] Arasaradnam R et al 2011 Insights into 'fermentonomics': evaluation of volatile organic compounds (VOCs) in human disease using an electronic 'e' nose J. Med. Eng. Technol. 35 87-91
    • [24] Arasaradnam R P et al 2012 Evaluation of gut bacterial populations using an electronic e-nose and efild asymmetric ion mobility spectrometry: further insights into 'fermentonomics' J. Med. Eng. Technol. 36 333-7
    • [25] Buszewski B et al 2007 Human exhaled air analytics: biomarkers of disease Biomed. Chromatogr. 21 533-66
    • [26] Goel A, Gupta M and Aggarwal R 2014 Gut microbiota and liver disease J. Gastroenterol. Hepatol. 29 1139-48
    • [27] Phillips M, Cataneo R N, Condos R, Erickson G A R, Greenberg J, La Bombardi V, Munawar M I and Tietje O 2007 Volatile biomarkers of pulmonary tuberculosis in the breath Tuberculosis 87 44-52
    • [28] Juzheng H, Kumar S, Singanayagam A, George P M, Kon O M, Takata M and Hanna G B 2013 Exhaled breath acetone for therapeutic monitoring in pneumonia using selected ion oflw tube mass spectrometry (SIFT-MS) Anal. Methods 5 3807-10
    • [29] Ge P S and Runyon B A 2014 Serum ammonia level for the evaluation of hepatic encephalopathy JAMA 312 643-4
    • [30] Henao-Mejia J, Elinav E, Thaiss C A and Flavell R A 2013 The intestinal microbiota in chronic liver disease Adv. Immunol. 117 73-97
    • [31] Loguercio C et al 2002 Gut-liver axis: a new point of attack to treat chronic liver damage? Am. J. Gastroenterol. 97 2144-6
    • [32] Covington J A, van der Schee M P, Edge A S, Boyle B, Savage R S and Arasaradnam R P 2015 The application of FAIMS gas analysis in medical diagnostics Analyst 140 6775-81
    • [33] Patel N et al 2014 Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inaflmmatory bowel disease: a pilot study Aliment. Pharmacol. Ther. 40 498-507
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article